Peginterferon alfa-2b (PEG)

BIOLOGICAL3 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Genotype 1HCV-1Hepatitis C, Chronic

Phase 3

Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED)

CompletedNCT00705432

Merck Sharp & Dohme LLCHepatitis C, Chronic

Start: 2008-08-31End: 2010-05-31Updated: 2017-04-07

Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)

CompletedNCT01390844

Merck Sharp & Dohme LLCHepatitis C, Chronic

Start: 2011-10-21End: 2015-06-19Updated: 2018-09-11

Unknown Phase

Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336)

CompletedNCT00863109

Merck Sharp & Dohme LLCGenotype 1, HCV-1, Hepatitis C, Chronic

Start: 2009-04-30End: 2013-05-31Updated: 2017-04-07

Related Papers

Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial.

2016-05-262 citations

Boceprevir for untreated chronic HCV genotype 1 infection.

2011-03-011792 citations